Essex Bio-Technology Limited (HKG:1061)

Market Cap	1.72B -29.8%
Revenue (ttm)	1.81B +8.6%
Net Income	318.09M +3.5%
EPS	0.56 +5.5%
Shares Out	567.01M
PE Ratio	5.42
Forward PE	5.33
Dividend	0.14 (4.61%)
Ex-Dividend Date	May 28, 2026

Volume	818,000
Open	3.000
Previous Close	3.040
Day's Range	2.910 - 3.110
52-Week Range	2.820 - 6.120
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 23, 2026

About Essex Bio-Technology

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. It operates through Ophthalmology, Surgical, and Healthcare and Partner Services segments. The company researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration. It offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 1,289
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1061

Financial Performance

In 2025, Essex Bio-Technology's revenue was 1.81 billion, an increase of 8.62% compared to the previous year's 1.67 billion. Earnings were 318.09 million, an increase of 3.54%.